The SYNERTIC strategy combining camrelizumab and apatinib for the treatment of unresectable advanced hepatocellular carcinoma after failure of first-line systemic therapy: A prospective, multicenter, single-arm, open-label, Phase II study

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2026
This article has no abstract
Epistemonikos ID: 19a4aee2f77c93ac984a178c9b72f62924f4476a
First added on: Oct 10, 2026